A Phase 1/2 interventional study of JNJ-64041757 and Nivolumab in Adenocarcinoma of Lung, sponsored by Janssen Research & Development, LLC. Terminated at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1/2, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Adenocarcinoma of Lung with a site in Spain — 3 open to participants now, 5 under way, none of them phase 3. Adenocarcinoma of Lung · Spain.
Among the 19 studies in Adenocarcinoma of Lung with a site in Spain, this one is the 18th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2018, is one of 3 in phase 1/2, and was the 13th registered.
418 studies on the registry are indexed under Adenocarcinoma of Lung; 78 are open to participants now.
Browse Adenocarcinoma of Lung studies →3 of the 19 studies in Adenocarcinoma of Lung with a site in Spain are open now. Recruiting first, the newest first:
Pfizer · Sites in Spain, United States, Canada and 3 more countries
Ages 18+
AstraZeneca · Sites in Spain, United States, Australia and 9 more countries
Ages 18–130
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Sites in Spain, United States, Greece and 1 more country
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 57 Adenocarcinoma of Lung studies recruiting now, 36 (63%) set no upper age limit and 10 (18%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 10 · Phase 3 3
First in 1995; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 60 across 293 interventional studies indexed under Adenocarcinoma of Lung.
Median enrollment 208 across the 18 interventional studies, 2,200 across the 1 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Johnson & Johnson has 1 study filed under Adenocarcinoma of Lung — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Adenocarcinoma of Lung with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate whether the efficacy of JNJ-757 combined with nivolumab is better than the efficacy of nivolumab monotherapy for participants with mesothelin-positive relapsed/refractory Stage IIIB or Stage IV adenocarcinoma of the lung. The open-label study comprises of two parts i.e. Phase 1b (safety run-in) and Phase 2. Phase1b consists of 1 arm whereas Phase 2 is randomized into 2 groups i.e. Group A and Group B.
This study evaluates safety and efficacy of JNJ-64041757 with nivolumab. The total study duration will be up to 3 years. It will consist of safety run-in and randomized phase which will comprise of Screening phase(Day(D) -28 to D -1),Treatment Phase,End of Adverse Event Evaluation Period (100 D after last dose of nivolumab)and Post-treatment Follow-up Phase(Every 3 Months). The primary hypothesis is that addition of JNJ-640417577 to nivolumab will result in higher objective response rate compared with nivolumab monotherapy in at least one of programmed death receptor ligand 1 subgroups in participants with relapsed or refractory StageIIIB or StageIV adenocarcinoma of lung. The study procedures include blood culture bacterial shedding assessments, pharmacokinetics, immunogenicity, and biomarkers. Safety will be monitored throughout study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1b and Phase 2 Group A/Arm 1: Participants will receive separate intravenous (IV) infusions of nivolumab and JNJ-64041757 over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
Biological: JNJ-64041757 · Drug: Nivolumab
Phase 2 Group B/Arm 2: Participants will receive intravenous (IV) infusions of nivolumab over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
Drug: Nivolumab
Participants will receive intravenous (IV) infusions of JNJ-64041757 over approximately 60 minutes during each treatment cycle.
Also known as: JNJ-757
Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.
Phase 1b: Percentage of Participants With Objective Response
Objective response rate was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST). RECIST for CR - disappearance of all lesions; all lymph nodes were non-pathological in size and normalization of tumor marker level; PR - greater than or equal to (\>=) 30 percent (%) decrease in the sum of the diameters of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of nontarget lesions.
Time frame: Up to 6.8 Months
Phase 1b: Duration of Objective Response (DOR)
Duration of objective response was defined as the time from initial documentation of a response (CR or PR) to first documented date of disease progression (PD) or death from any cause. RECIST for PD - sum of diameters had increased by \>= 20% and \>=5 mm from nadir (including baseline if it was smallest sum). Participants with measurable disease: for "unequivocal progression" based on non-target disease, there was an overall level of substantial worsening that merits discontinuation of therapy (if target disease is stable disease \[SD\]/PR). Participants without measurable disease: for "unequivocal progression" of non-target disease, increase in overall tumor burden must be comparable to increase required for PD of measurable disease. Furthermore, appearance of 1 or more new lesions or unequivocal progression of a non-target lesion.
Time frame: Up to 6.8 months
Phase 1b: Number of Participants With Progression-free Survival (PFS) Event (Progressed or Died Before Progression)
Number of participants with PFS event (progressed or died before progression) were reported. PFS - time from date of randomization until date of first documented evidence of PD (or relapse for participants who experience CR during study) or death from any cause, whichever comes first. RECIST for PD - sum of diameters had increased by \>= 20% and \>=5 mm from nadir (including baseline if it was smallest sum). Participants with measurable disease: for "unequivocal progression" based on non-target disease, there was an overall level of substantial worsening that merits discontinuation of therapy (if target disease is SD/PR). Participants without measurable disease: for "unequivocal progression" of non-target disease, increase in overall tumor burden must be comparable to increase required for PD of measurable disease. Furthermore, appearance of 1 or more new lesions or unequivocal progression of a non-target lesion.
Time frame: Up to 6.8 months
Phase 1b: Number of Participants With Overall Survival (OS) Event (Died)
Number of participants with OS event (died) were reported. Overall Survival was defined as the duration from the date of randomization to the date of participant's death due to any cause.
Time frame: Up to 6.8 months
Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as adverse events with onset or worsening on or after date of first dose of study treatment.
Time frame: Up to 6.8 months
Phase 1b: Number of Participants With Positive Blood Culture
Number of participants with surveillance cultures positive for listeriosis were reported.
Time frame: Up to 6.8 months
Phase 1b: Number of Participants With Bacterial Shedding
Number of participants with bacterial shedding were reported. The shedding of JNJ-64041757 was studied in feces by stool or rectal swab, urine and saliva.
Time frame: Up to 6.8 months
Phase 1b: Serum Concentrations of Nivolumab
Nivolumab serum concentrations were reported.
Time frame: Up to 6.8 months
Phase 1b: Number of Participants With Anti-nivolumab Antibodies
Number of participants with antibodies to nivolumab were reported.
Time frame: Up to 6.8 months
| Milestone | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| Started | 12 |
| Completed | 0 |
| Not completed | 12 |
| Withdrew: Death | 5 |
| Withdrew: Study terminated by sponsor | 3 |
| Withdrew: Other | 4 |
Objective response rate was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST). RECIST for CR - disappearance of all lesions; all lymph nodes were non-pathological in size and normalization of tumor marker level; PR - greater than or equal to (\>=) 30 percent (%) decrease in the sum of the diameters of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of nontarget lesions.
| Percentage of participants | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| Phase 1b: Percentage of Participants With Objective Response | 0 |
Duration of objective response was defined as the time from initial documentation of a response (CR or PR) to first documented date of disease progression (PD) or death from any cause. RECIST for PD - sum of diameters had increased by \>= 20% and \>=5 mm from nadir (including baseline if it was smallest sum). Participants with measurable disease: for "unequivocal progression" based on non-target disease, there was an overall level of substantial worsening that merits discontinuation of therapy (if target disease is stable disease \[SD\]/PR). Participants without measurable disease: for "unequivocal progression" of non-target disease, increase in overall tumor burden must be comparable to increase required for PD of measurable disease. Furthermore, appearance of 1 or more new lesions or unequivocal progression of a non-target lesion.
No measurements were reported for this outcome.
Number of participants with PFS event (progressed or died before progression) were reported. PFS - time from date of randomization until date of first documented evidence of PD (or relapse for participants who experience CR during study) or death from any cause, whichever comes first. RECIST for PD - sum of diameters had increased by \>= 20% and \>=5 mm from nadir (including baseline if it was smallest sum). Participants with measurable disease: for "unequivocal progression" based on non-target disease, there was an overall level of substantial worsening that merits discontinuation of therapy (if target disease is SD/PR). Participants without measurable disease: for "unequivocal progression" of non-target disease, increase in overall tumor burden must be comparable to increase required for PD of measurable disease. Furthermore, appearance of 1 or more new lesions or unequivocal progression of a non-target lesion.
| Participants | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| Phase 1b: Number of Participants With Progression-free Survival (PFS) Event (Progressed or Died Before Progression) | 10 |
Number of participants with OS event (died) were reported. Overall Survival was defined as the duration from the date of randomization to the date of participant's death due to any cause.
| Participants | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| Phase 1b: Number of Participants With Overall Survival (OS) Event (Died) | 5 |
An adverse event is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as adverse events with onset or worsening on or after date of first dose of study treatment.
| Participants | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 12 |
Number of participants with surveillance cultures positive for listeriosis were reported.
| Participants | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| Phase 1b: Number of Participants With Positive Blood Culture | 1 |
Number of participants with bacterial shedding were reported. The shedding of JNJ-64041757 was studied in feces by stool or rectal swab, urine and saliva.
| Participants | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| Phase 1b: Number of Participants With Bacterial Shedding | 0 |
Nivolumab serum concentrations were reported.
No measurements were reported for this outcome.
Number of participants with antibodies to nivolumab were reported.
| Participants | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| Phase 1b: Number of Participants With Anti-nivolumab Antibodies | 6 |
Collected over Up to 6.8 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b: JNJ-64041757+ Nivolumab | 5/12 (41.7%) | 5/12 (41.7%) | 12/12 (100%) |
| Event | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/12 |
| Abdominal PainGastrointestinal disorders | 1/12 |
| Intestinal ObstructionGastrointestinal disorders | 1/12 |
| Non-Cardiac Chest PainGeneral disorders | 1/12 |
| Oedema PeripheralGeneral disorders | 1/12 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/12 |
| Back PainMusculoskeletal and connective tissue disorders | 1/12 |
| Musculoskeletal PainMusculoskeletal and connective tissue disorders | 1/12 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/12 |
| ErythemaSkin and subcutaneous tissue disorders | 1/12 |
| Event | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| PyrexiaGeneral disorders | 8/12 |
| ChillsGeneral disorders | 7/12 |
| AstheniaGeneral disorders | 6/12 |
| AnaemiaBlood and lymphatic system disorders | 5/12 |
| NauseaGastrointestinal disorders | 5/12 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/12 |
| Decreased AppetiteMetabolism and nutrition disorders | 4/12 |
| VomitingGastrointestinal disorders | 3/12 |
| HyponatraemiaMetabolism and nutrition disorders | 3/12 |
| Musculoskeletal PainMusculoskeletal and connective tissue disorders | 3/12 |
The all treated analysis population consisted of participants who received at least 1 dose of study agent.
| Age, Continuous(years) | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| Mean | 61.2 ± 12.63 |
| Sex: Female, Male(Participants) | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| Female | 4 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 11 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 12 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| Hispanic or Latino | 1 |
| White Non-Hispanic | 11 |
| Region of Enrollment(Participants) | Phase 1b: JNJ-64041757+ Nivolumab |
|---|---|
| SPAIN | 10 |
| UNITED STATES | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2018 to primary completion in Oct 2018, 9 months.
Results were first posted in Dec 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen Research & Development, LLC →